The Neurotech Investing and Partnering Conference 2011

San Francisco, CA
Monday, May 09, 2011

Click here for The Neurotech Investing & Partnering Conference 2012  

AGENDA
Location:  St. Regis San Francisco

Monday May 9, 2011







7:00 

Breakfast & Registration


8:00

Welcome: The Global Neurotech Industry 2011



Casey Lynch
Managing Director, NeuroInsights




8:30

Investing in Neurotech Panel



A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Bruce Leuchter
Director, Clinical Neuropsychiatry & Neurostimulation Therapies, Weill Cornell Medical College

Luke Evnin
Managing Director, MPM Capital

Kiran Reddy
Principal, Third Rock Ventures

Kevin Wasserstein
Managing Director, Versant Ventures

Ilan Zipkin
Partner, Prospect Venture Partners

Mark McInerney
Visium Asset Management



9:30

Networking and Refreshment Break


 


 

10:00

Beyond the BBB: Gene Therapy, Cell Implants and Drug Delivery

 


Companies present novel approaches for delivering new therapeutics for the brain and nervous system including gene therapy, cell therapy, protein conjugates and neurodevice innovations.


 

 
Session Chair: John Reher
Partner, Brain Trust Accelerator Fund

Jeff Ostrove
CEO, Ceregene

Erich Mohr
Chairman & CEO, MedGenesis Therapeutix

Lars Wahlberg
Executive Vice President and COO, NsGene

 

Jean-Paul Castaigne
CEO, AngioChem

 

 

11:00

Alzheimer's and MCI

 

 

As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

 

 


Session Chair: Stephen Knight

Managing Partner, Fidelity Bioscience


Kees Been
CEO, EnVivo Pharmaceuticals


Jeff Ives

CEO, Satori Pharmaceuticals

Jonathan Solomon
CEO, NeuroPhage

Eyal Baror
CEO, Neuronix Medical

Daniel O'Connell
CEO, Functional Neuromodulation, Inc.

 



 

12:15

Lunch Keynote




The Most Important Financial Decision Facing CNS Companies: The True Cost of Risk - Paul Gilbert, CEO MedAvante

 

1:45

Internal and External Research & Development



What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?


 


Session Chair:
Liam Ratcliffe

General Partner, New Leaf Venture Partners


Lothar Krinke

VP of Research and Business Development, Medtronic Neuromodulation

 
Jeffrey Nye

VP and Head External Innovation for Neuroscience, Johnson & Johnson


Larry Altstiel
Vice President, Head of Neuroscience Clinical Research, Pfizer

Alexander Schuth

Head of Neuroscience Partnering, Genentech

 

 

3:00 

Networking and Refreshment Break

 



 

3:30

Orphan Disorders: ALS, Huntington's, Friedreich's Ataxia and more


 

With regulatory and reimbursement approvals becoming more difficult, the profile of orphan disorders is on the rise.  Companies have now shown that premium pricing for orphan disorders can propagate a highly successful business model. What new treatments are on the horizon?

 

 

 

Session Chair: Jennifer King

Senior Director, Scientific Licensing and Business Development, Shire


Andrew Gengos

CEO, Neuraltus


Jay Lichter
CEO, Afraxis & Managing Director, Avalon Ventures

Steve Orndorff

CEO, Ariel Pharmaceuticals

Anthony Ignagni

CEO, Synapse Biomedical

 

 

4:30

New Business Models in Neurotechnology

 

 

With venture capital steering away from long term and risky investments, neurosoftware, neurofeedback, neuromarketing and other new business models represent far lower risk and faster times to market.  What winning strategies are emerging in brain fitness, sleep management, neuroplasticity, and human performance?

Session Chair: Roger Quy
General Partner, Technology Partners

Henry Mahncke
CEO, Posit Science

Chris Berka
CEO and Co-Founder, Advanced Brain Monitoring


David Dickinson
CEO, Zeo


Stanley Yang
CEO, NeuroSky

 

 

 

 

5:30

Networking Reception




 

Tuesday May 10, 2011



                           

 



7:00      

Continental Breakfast & Registration




 

8:00

Partnering and Licensing in Neurotech Panel



Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions?  With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2011?



 

Moderator: Christine de los Reyes

Managing Director, BiotechPartnering Solutions

Peter Lando
Vice President of Intellectual Property & Business Development, St. Jude Medical

 

Erik Nielsen
Director, Scientific Licensing, Corporate Business Development & Strategy

H. Lundbeck A/S


Mark Nuttall
VP Licensing, Neuroscience and EMEA, Johnson & Johnson

Kenneth Maynard

Global Head, Business Development, Aging, Sanofi-Aventis

Alethia de Leon
Head of Search & Evaluation, Neuroscience and Ophthalmics, Global BD&L, Novartis

 

 



   

9:15

Networking and Refreshment Break




 

9:45 

Frontiers in Neurotechnology

 


In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including sensory disorders, hypertension, obesity, sleep apnea, neuroimmunology and many others. New technology developed in other fields is yeilding benefits in neurodiagnostics. Exciting new platforms leveraging cutting edge techniques are being used for drug discovery. Don't miss this preview of next generation products and companies.




Session Chair: Vincent Kim
Partner, Aberdare Ventures

Karoly Nikolich
CEO, Circuit Therapeutics

Daniel DiLorenzo

Founder and CEO, DiLorenzo Biomedical

Dean Gray
Business Development, Heidelberg Engineering

Laura Perryman
CEO, Stimwave Technologies


Ben Pless
President & CEO, Autonomic Technologies

 

     

11:00

Next Generation Psychiatry


 

Schizophrenia, anxiety, depression, addiction and other psychiatric illnesses represent a large portion of the neurotech market.  What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?


Session Chair: Manuel Lopez-Figueroa

Vice President, Bay City Capital

 
Anthony McKinney
CEO, Euthymics Bioscience


Jay Shepard

President & CEO, NextWave Pharmaceuticals


Eric Meier

CEO, Neostim

Lonna Williams

CEO, Ridge Diagnostics

 



 

12:00

Partnering Lunch sponsored by The Neurotechnology Industry Organization


 


 

1:00

Strategies for CNS Drug and Device Development


 

Through case studies, drug and device companies will discuss lessons learned and current issues in discovery, animal models, clinical trial design, regulatory hurdles, reimbursement challenges, financing and partnering. Regulatory and clinical experts will join the discussion to highlight changes at the FDA and strategies for changing current paradigms in CNS treatment development.

Session Chair: Michael Grey
Venture Partner, Pappas Ventures

 

 


Scott Cullison

Sr. Director, Business & Commercial Development, Targacept

Amir Kalali
Vice President, Global Medical Therapeutic Head, CNS, Quintiles

Frank Fischer
CEO, Neuropace

Suzan Onel

Partner K&L Gates, NIO Regulatory Counsel

 

 
 

2:30

Networking and Refreshment Break

 

 

 

 

3:00

Pain, Epilepsy, & Migraine

 

 

Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain.

 
Session Chair: Joyce Cramer

Executive Director: Epilepsy Therapy Project


John Andrews

CSO, NeurAxon

Gail Farfel

Chief Clinical Development Officer, Marinus Pharmaceuticals


Leon Ekchian
President and CEO, NeuroSigma


David Wood
President and CEO, Spinal Modulation

 

 


 

4:00

NIO Working Group



An overview and participant discussion of current and future congressional, FDA, and CMS initiatives to advance neurotech.

Zack Lynch
Executive Director, Neurotech Industry Organization

John Reppas
Director of Public Policy, Neurotech Industry Organization

Daniel Ritter
Partner, K&L Gates, NIO Public Policy Counsel


5:00        

Conference Concludes


 

 

Contact Information